Hope on the Horizon: Nephrologists Emphasize Need for Innovative C3G Treatments as Novartis and Apellis Prepare Therapies for FDA Submission
November 15, 2024 13:15 ET
|
Spherix Global Insights
EXTON, PA, Nov. 15, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare, progressive kidney disease characterized by inflammation and kidney damage. Patients with C3G often...
Novartis' Fabhalta Shows Promise in Addressing Critical Gaps in C3 Glomerulopathy Treatment
June 13, 2024 11:39 ET
|
Spherix Global Insights
EXTON, PA, June 13, 2024 (GLOBE NEWSWIRE) -- Complement 3 glomerulopathy (C3G) is a rare kidney disease that presents significant challenges for both patients and nephrologists. Currently, there are...
Complement 3 Glomerulopathy Market to Witness an Upsurge in Growth by 2023, Predicts DelveInsight | Key Companies to Watch - Novartis, Apellis, NovelMed, Amyndas, Arrowhead
November 06, 2023 13:00 ET
|
DelveInsight Business Research LLP
New York, USA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Complement 3 Glomerulopathy Market to Witness an Upsurge in Growth by 2023, Predicts DelveInsight | Key Companies to Watch - Novartis, Apellis,...
Achillion to Present at the Leerink Partners 7th Annual Global Healthcare Conference
February 09, 2018 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Feb. 09, 2018 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today that Milind Deshpande, Ph.D., President and Chief Executive Officer of Achillion,...
CORRECTION - Achillion Pharmaceuticals, Inc.
December 20, 2017 12:12 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- In the news release issued earlier today by Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), please be advised the headline should read "Achillion...
Achillion Initiates Phase I First-In Study of ACH-5228, a Next-Generation Oral Small Molecule Inhibitor of Complement Factor D
December 20, 2017 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Dec. 20, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a pharmaceutical company focused on advancing small molecule inhibitors of factor D in the...
Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs
November 01, 2017 16:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended September 30, 2017. For the third...
USPTO Grants Composition of Matter Patent to Achillion for ACH-4471, First-in-Class Small Molecule Complement Alternative Pathway Factor D Inhibitor
October 24, 2017 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., Oct. 24, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that the U.S. Patent and Trademark Office (USPTO) has issued a U.S. Patent to...
Achillion Reports Second Quarter 2017 Financial Results and Proof-of-Concept With a First-in-Class, Oral Factor D Inhibitor
August 08, 2017 16:01 ET
|
Achillion Pharmaceuticals, Inc.
- Interim results demonstrate ability of ACH-4471 to reduce LDH and improve hemoglobin and fatigue scores in patients with untreated PNH - - Global program expansion planned in PNH, C3G and IC-MPGN -...
Achillion Reports First Quarter 2017 Financial Results and Provides Update on Clinical Programs
May 04, 2017 06:05 ET
|
Achillion Pharmaceuticals, Inc.
NEW HAVEN, Conn., May 04, 2017 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today reported financial results for the three months ended March 31, 2017. For the first quarter of...